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Antibody used in a steroid radlolmmunoassay raised against a steroid 
hapten-carrier protein conjugate may recognize both the hapten and the 
chemical bridge to the protein. Use of the same bridge in the radio- 
isotopic label may lead to higher affinity binding to the label than 
to the native steroid. Inhibition curves under these conditions are 
shallow and generally not acceptable for radioimmunoassay procedures. 
We have developed a radloimmunoassay for androstenedlone that employs 
different bridges a~ the 118 position of the steroid for the protein 
conjugate and label. The resulting assay has greatly reduced bridge- 
binding, has an acceptable slope for the standard curve and is very 
specific as evidenced by low crossreaetivles to other steroids. 
INTRODUCTION 
To develop a radloimmunoassay (RIA) for measuring steroids, 
antibodies for the assay are produced using a steroid hapten-carrier 
protein conjugate. The resulting antibodies often recognize and 
demonstrate high affinity binding to both the steroid and the chemical 
bridge through which the hapten was attached to the carrier protein. 
This phenomena is referred to as bridge-binding (I-8). Use of 1251 as 
the radionuclide to produce a labeled trace for the RIA requires that 
the iodinated functional group, phenol or imidazole, be attached to 
the steroid with a chemical bridge. However, if the label-bridge is 
homologous to the conjugate-bridge, the antibodies will have a higher 
affinity for the label than the native steroid. Consequently, the 
amount of steroid required to displace the radiolodlnated steroid will 
be so great that the standard curve will shift to the right resulting 
in a substantial loss of sensitivity. In addition, the slope of the 
curve will be very shallow causing a loss of precision. 
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Recently we reported (I) on a procedure for reducing bridge- 
binding in a RIA for androstenedione (9). By using both a succinyl 
ester linkage (-02CCH2CH2CO2-steroid) and an ether linkage (-NHCOCH20- 
steroid) attached to the 19 position of androstenedione, we were able 
to obtain a very sensitive and precise RIA. Unfortunately, the anti- 
sera, which was produced in sheep, was not very specific. The assay 
had a high crossreactivity towards closely related steroids, such as 
5e-androstanedione, dehydroepiandrosterone and androsterone. Later, 
Racet al reported (10) a RIA using a tritiated label and rabbit 
antibody against a bovine serum albumin-androstenedione conjugate 
(BSA-NHCOCH20-19-androstenedione) which was structurally identical to 
one that we had used (I). Although their rabbit antibody was more 
specific than the sheep antisera, it exhibited high nonspecificity to 
5a-androstanedlone and crossreactivity of about 2% or more to 
testosterone, dehydroepiandrosterone and androsterone. 
We wish to report a RIA that employs sheep antibody against 
androstenedione linked to BSA with an ether bridge at the 118 position 
of the steroid (BSA-NHCOCH20-11B-androstenedione) and a label that has 
an ester bridge (1251-phenol-CH2C02-11 6-androstenedione ). The 
resulting assay is very sensitive and precise. In addition, the 
crossreactlvities of the antibody against testosterone, androsterone 
and dehydroepiandrosterone are at least ten-fold less than those 
reported by Rao et el (10). 
MATERIALS 
Na[125I] (carrier free) was obtained from New England Nuclear. 
11~-hydroxyandrostenedlone, 1-ethyl-3-(3-dimethylaminopropyl)- 
carbodlimlde, dehydroeplandrosterone, testosterone, 5~-dihydro- 
testosterone, pigskin gelatin, bovine serum albumin and merthiolate 
(thimerosal) were obtained from Sigma Chemical Co. Ethyl diazo- 
acetate, p-toluenesulfonic acid and p-hydroxyphenylacetic acid were 
purchased from Aldrich Chemical Co. Chloramine-T and sodium meta- 
bisulfite were from J.T. Baker Co. Androstenedione, androsterone, 
5@-androstenedione, progesterone and estradiol-178 were purchased from 
Steraloids Inc., Wilton, N.H. RhCI~.BH20 was from Ventron Corporation 
and HPLC grade acetonitrile was from Burdick & Jackson Laboratories, 
Muskegon, MI. Other solvents were analytical grade. Steroids used as 
RIA standards and crossreactants were recrystallized. 
SYNTHESES 
The syntheses of the conjugate and radioiodinated label used in 
this study are outlined in figure I. Melting points were determined 
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in capillary tubes in a Thomas-Hoover apparatus and were corrected. 
Spectral analyses were obtained with the following instruments: IR, 
Perkin-Elmer 281; NMR, Varian EM-360; and UV, Cary 219. 
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Figure I. Synthetic Schemes 
]_~-(Carboxvmethoxv)-4-androstene-~.17-dio~e (II). 11B-hydroxy- 
androstenedlone (250 mg, 0.84 mmol) was dissolved in dry benzene (40 
mL). The catalyst Rh~(O~CCH~) 4 (3 mg), prepared from RhCI~.H20 (11), 
was then added. Ethyl @iazdacetate (1.09 gm, 9.51 mmol) ~as added 
dropwise to the steroid solution. Additlonal ethyl diazoacetate (2.18 
gm, 19.02 mmol) was added 6 hr later, and the reaction stirred at room 
temperature overnight. The reaction mixture was poured into H20 (100 
mL) and extracted five times with CHC13 (50 mL). The combined organic 
layer was dried with Na2SO 4 and evaporated invacuo yielding a yellow 
oil. The oil was chromatographed on a 1.5 x 30 cm silica gel column 
using a 0 to 2% CH3OH gradient in CHCl~ for elution. A second chroma- 
tography step on a 1.5 x 30 cm silica ~el column with a 0 to 20% ethyl 
acetate gradient yielded 118-(ethylcarboxymethoxy)-4-androstene-3,17- 
diode as a clear oil (120 mg, 37.4%). IR (CHCl~), !max 1740 and 1668 
cm-': NMR (CDCI~),~ 1.10 (s,3H, 18-C~), 1.26~(t J=8.0 cps,3H, 
-OCHoC~), 1.52~(s,3H, 19-C~), 4.10 qm,5H, I~-OC~2CO2-,-OC~2CH3 , 
11~-_~),~5.72 (s,IH,4-_H). Ana~. Calc. C2~H~oO~: C,71.11;H,8.30. Found: 
C,71.15;H,8.26. ~ ~ 
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The ethyloarboxymethoxy derivative from above (135 mg, 0.346 mmol) 
was dissolved in CH~OH (10 mL). KOH (6.4 mL of 0.1 ~, 0.70 mmol) was 
added dropwise at I~°C. The reaction mixture was then poured into 
saturated NaC1 solution (200 mL) and made slightly acidic with I 
HCI. The resulting aqueous mixture was extracted six times with CHCI_ 
(10 mL). The combined organic phase was dried as above and evaporate~ 
in vaouo yielding 11B-(carboxymethoxy)-androstene-3,17-dione (II) a~.a 
clear oil (120 mg, 96%). IR (CHCI3) , Vmax 3400, 1739 and 1668 cm • 
NMR (CDCI~), ~ 1.07 (s,3H,18-C~), 1.50 (s,3H, 19-C~), 4.05 (s,2H, 
-OC~CO~H~, 4.18 (m,1H,11~-H),~5.75 (s,IH,4-~H), 6.0~ (broad s,IH, 
-CO2~H,e~changed with D20 ). -- 
l~8-FN-(Bovine serum albumin)-~m~docarboxvmethoxv]-4-androstene-R.17- 
dione (III)~ The carboxymethoxy derivative II (100 mg, 0.28 mmol) was 
dissolved in dimethyl formamide (10 mL) and H~O(4 mL). 1-Ethyl- 
3-(3-dimethylaminopropyl)-carbodiimide (EDAC) 6100 mg, 1.92 mmol was 
added, and the mixture stirred for 30 min. Bovine serum albumin (BSA) 
(200 mg) dissolved in phosphate buffer (0.01 ~, pH 7.8, 20 mL) was 
added dropwise to the steroid solution which was stirred two days at 
ambient temperature in the dark. The solution was dialyzed against 
0.05 M NaHCO~ (2 x 2 L) and H~O (4 x 2 L) and lyophilized. The molar 
ratio--of th~ steroid to protein was found to be 15.0 by spectral 
analysis (I). 
1_~-(o-Hvdroxvnhenvlacetoxv)-4-androstene-~.17-dione (IV). p-Toluene- 
sulfonic acid (160 mg, 0.842 mmol) was dissolved in benzene (30 mL), 
and the mixture refluxed with a Dean-Stark apparatus for 3 hr to 
remove H20. 11B-Hydroxyandrostenedione (100 mg, 0.33 mmol) and 
p-aoetoxyphenylacetic anhydride (I) (200 mg, 0.54 mmol) were added to 
the benzene solution and the resulting mixture was refluxed for 10 
additional min, cooled to room temperature and stirred 48 hr. The 
reaction mixture was poured into H20 (100 mL) and extracted six times 
with CHCl~ (30 mL). The combined organic layer was dried as before 
and evaporated in vacuo yielding a clear oil. The oil was dissolved 
in methanol (5 mL), 4 drops of saturated NaHCO~ were added, and the 
mixture stirred fo 1.5 hr. The pH of the solutfon was adjusted to 2.0 
with 0.5 ~ HCI and extracted five times with CHCl~ (15 mL). The 
chloroform layer was washed twice with H20 (10 mL) ~nd dried. Removal 
of the solvent left a yellow oil that was purified on a 1.5 x 30 cm 
silica gel column. Elution with benzene/ethyl acetate (4/I) yielded a 
clear oil. Recrystallization from acetone/hexane produced IV as a 
white solid (84 ~ 58%) mp 154-155 °C. IR (CH2C12), lmax 3609 , ~730, 
1670 and 1525 cm" : NMR (CDCI~), 8 0.78 (s,3H,18-C~3), 1.14 (s,~n, 
19-C~_o), 3.50 (s,2H, phenyl-C~o~O2-), 4.49 (m,1H,11~), 5.71 (s,IH, 
4-H),~6.76 and 7.11 (dd J=I0.~5 ops,hH, phenyl-~), 7.80 (broad s,IH, 
phenyl-O~, exchanged with~). Anal. Cale. C27H3205: C, 74.29; H, 
7.39. Found: C, 74.41; H, . • 
of IV, The p-hydroxyphenyl derivative IV (2.0 ug, 
4.58 nmol) in ethanol (2 uL) was placed in a I mL vlal fitted with a 
multi-dose ~tum. Phosphate buffer (0.5 ~, pH 7.4, 40 uL) and 
aqueous Na[ I] (4.0 mCi, 11.2 uL) were added. The iodination was 
initiated by the addition of ohloramine-T (20 ug, 106.5 nmol) in 
phosphate buffer (0.05~, pH 7.4, 30 uL) (buffer A). After shaking at 
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ambient temperature for I mln, the reaction was quenched by the 
addition of sodium metabisulfite (10 ug, 52.5 nmol) in buffer A (20 
uL). Purification of the radioiodinated steroid was done by HPLC. 
The entire reaction mixture was injected onto an Altech 600-RPA C1g 
reverse phase column using a Rheodyne injector fitted with a 100 ~E 
loop. A Spectro Physics SP8700 pump provided the following mobile 
phase at a flow rate of I mL/min: 0 to 5 min, an isocratic mixture of 
20% acetonitrile in 0.05 ~ potassium formate buffer, pH 4.0; 5 to 80 
min, a 20 to 60% gradient of acetonitrile in the formate buffer. The 
eluted material was collected in a Gilson FC-80 Fraction Collector (I 
min fractions), and the radioactivity was quantitated with a gamma 
counter. Both a monoiodinated (eluting at 65 min) and a diiodinated 
derivative (77 min) of the steroid were isolated. The estimated 
specific activity (12) of the two labels were found to be 3.3 mCi/ug 
and 5.4 mCi/ug, respectively . The monolodinated label, which was used 
in the RIA, had a maximal binding (active fraction) of 98% in the 
presence of exess antibody. 
METHODS 
Antibody ~ Antibody against the steroid-BSA conjugate III 
was raised in five Suffolk ewes. Two milligrams of the conjugate in 
Freund's complete adjuvant (1.0 mL) was injected intradermally at 
multiple sites on the flanks of each animal. Booster injections of 
1.0 mg in incomplete Fruend's adjuvant (1.0 mL) were given at weeks 4 
and 8. Bleedings were taken at weeks 10 and 11 and the highest titers 
(dilution of serum needed to bind 50% of the label) were found at week 
11. Serum from sheep #95, which had the best specificity, was used 
for the RIA. 
Radioimmunoassav. The radioimmunoassay was run as described 
previously (I) using a 1/50,000 dilution of antisera and 40,000 
cpm/tube of label. Crossreactivity studies were done using the method 
of Thorneycroft et'al (13). 
RESULTS AND DISCUSSION 
It was obvious from our previous paper (I) that bridge-binding 
could be significantly reduced in a RIA for androstenedione by employ- 
ing heterologous bridges when synthesizing the immunogenic steroid- 
carrier protein conjugate and the 125I-steroid label. It was also 
apparent that use of the 19 position of the steroid for functional- 
izatlon introduced problems of specificity. Consequently, we chose to 
use the same type of linkages but at a different position, namely, the 
11B position of androstenedione. When antibody against an ether- 
linked BSA conjugate (BSA-NHCOCH20-11B-androstenedione) was used in 
conjunction with an ester-linked label (1251-phenol-CH2CO2-11B-andro- 
stenedione), we obtained a standard curve with a 50% inhibition point 
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of 104 pg/tube and a slope of -I.73. The 509 point was somewhat 
higher than that reported previously (I) (104 pg vs. 15 or 76 pg). 
However, the actual limit of detection (14) is certainly adequate for 
routine use (200 femtograms (fg)/assay tube). The slope of -1.73 was 
less than the ideal -2.303 for a logit-log curve but provides a work- 
able assay. 
The most obvious improvement was in assay specificity as can be 
seen in table I which compares the crossreactivity of our current 
assay using antibody against the 11~-conJugate to the cross- 
reactivltles we reported (I) and those Rao ~_~ al reported (10) using 




Anti-19 (1) Ra.o et  a l  (10) 
Androstenedione 100.0 100.0 100.0 
5~-Androstanedione 5.2 61.7 30.38 
Testosterone 0.06 0.05 2.50 
5a-Dihydrotestosterone 0.17 0.04 1.55 
Dehydroepiandrosterone 0.21 10.0 2.54 
Androsterone 0.14 48.1 1.93 
Progesterone 0.26 0.03 0.55 
Estradiol-176 0.007 0.08 0.08 
The crossreactivity of the 11S-system to 5a-androstanedione is 
5.2% vs. 61.7% and 30.38% for the two 19-systems. Antibodies to 
androgens, such as androstenedlone and testosterone, usually cannot 
differentiate very well between the 4-ene and 5~- forms of the 
steroids (15-18). The best evidence for improved specificity lies in 
the comparison of the crossreactivities of dehydroepiandrosterone and 
androsterone. We obtained 0.21% and 0.14%, respectively, compared to 
10.0% and 48.1% for the anti-19-conJugate (I). Although Racet al 
(10) reported antlsera (rabbit) to the 19-conjugate with higher 
specificity than we described (sheep) using the same immunogen (1), 
the rabbit antibodies are at least 10-fold less specific than the 
anti-liB-conjugate antibodies. In addition, the anti-116-antlserum 
also has lower crossreactlvity to testosterone and 5~-dihydro- 
testosterone than that reported for the rabbit anti-19-conJugate (10). 
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The crossreactivity of antl-androstenedione antisera to testosterone 
and dehydroepiandrosterone is critical since they are present in male 
human serum samples at concentrations greater than or equal to the 
amount of androstenedione (19) and would interfere in a RIA. 
In conclusion, by using the heterologous bridges we described 
previously (I), a sensitive and precise steroid radioimmunoassay can 
be developed. This is evidenced by the assay limit of detection of 
200 fg/tube and slope of the inhibition curve of -1.73. In addition, 
one can produce very specific antibodies by using the 118 position of 
androstenedione for attachment of the carrier-proteln and labeled 
functional groups. 
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